Ubiquigent™ has the assays, expertise, and capabilities to drive forward every step in the drug discovery workflow for DUB-focused therapeutic applications, from targeting DUBs as the drug target to harnessing them for the modulation or stabilisation of a given disease protein.
End-to-end platform for DUB-focused drug discovery and development
Our specialised drug discovery platform and long-standing expertise is empowering scientists to develop DUB inhibitors, DUB-targeting PROTACs, and DUBTACs into exciting new medicines
Suite of comprehensive biochemical and cellular assays
DUBprofiler
Widely cited, comprehensive and flexible profiling assay to characterise novel DUB-binding ligands to establish their potency and selectivity
DUBprofiler-Cell and DUBprofiler-Tissue
Flexible assays to determine target engagement and selectivity of DUB inhibitors in cell lysates, cell cultures, or tissue samples
PROTEOMEprofiler
Mass spectrometry-based assay that rapidly profiles the entire proteome to identify and validate DUB targets in disease and determine the mechanism of action for therapeutics targeting the UPS
REDOXprofiler
Critical counter-screening assay that separates false positives from genuine hits
DUBmechanism
Customised assays to investigate the mechanism of action of novel DUB targeting compounds
UBISITEprofiler
Unique ubiquitinomics assay for the comprehensive, unambiguous, and unbiased analysis of ubiquitination sites across the full proteome
DUBseeker
Comprehensive set of assays to identify the most appropriate DUB partner for a given target protein to drive the development of DUBTACs
DUBatlas
Proprietary toolkit for mapping the active DUBome in diseased vs non-diseased human or animal tissues, cells, or subcellular compartments
DUBscan
The generation of physiologically ubiquitinated target proteins and their *in vitro* deubiquitination using a panel of DUBs
DUBselect
Proximity profiling assay to generate cell-based proof-of-principle that induced proximity with a given DUB leads to stabilisation of a target protein and the desired phenotype
DUBbinder
Assay to identify novel compounds that bind selected DUBs
Custom Assay Development
Bespoke assays to screen compounds against exciting new DUB targets as they continue to emerge across a wide range of human diseases
Chemistry expertise to design novel compounds
Proprietary DUB-targeting compounds
Novel compounds to provide new starting points for DUB-focused drug discovery programmes
Ubiquigent has a growing collection of novel DUB-targeting compounds that have been evaluated across our suite of comprehensive biochemical and cellular assays. These compounds represent a valuable resource for identifying new starting points for DUB-focused drug discovery programmes.
Highly experienced chemists in DUB drug discovery
Our chemists have worked on the design and development of DUB-binding ligands for our internal pipeline and on behalf of our clients
Ubiquigent chemists are experienced at applying computational and medicinal skills to the design of DUB ligands, encompassing covalent and non-covalent compounds, and compounds with an allosteric mechanism of action. They also have substantial experience in developing orally bioavailable heterobifunctional molecules.
Access to a range of relevant technologies through our growing network of collaborators and industry experts, including in structural biology
Ubiquigent has established a network of academic and industrial partners to augment our own experience, including structural biology, mass spectrometry and individual DUB target-based expertise. These existing partnerships alongside new collaborations, as appropriate, can be leveraged to offer our clients an even more comprehensive DUB-focused partnership.